Related Experiment Video

Updated: Dec 28, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.4K

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors for Cardiovascular Disease Prevention

Jessica Reid1,2, Khyatiben Rana1, Stephanie Niman1

  • 1East Coast Institute for Research, 3550 University Blvd. South, Suite 101, Jacksonville, FL, 32216, USA.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|February 12, 2020
PubMed

Insights

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors show promise in reducing cardiovascular events for type 2 diabetes mellitus patients. These SGLT-2 inhibitors offer potential cardiovascular benefits, especially for those with existing heart conditions.

Area of Science:

  • Endocrinology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a major cause of death in type 2 diabetes mellitus (T2DM) patients.
  • Despite preventive therapies, residual risk for atherosclerotic CVD (ASCVD) remains high in T2DM.
  • Managing T2DM and CVD, including heart failure (HF), is crucial for reducing adverse outcomes.

Purpose of the Study:

  • To review the cardiovascular benefits of SGLT-2 inhibitors in T2DM patients.
  • To evaluate the role of SGLT-2 inhibitors in preventing major adverse cardiovascular events (MACE).
  • To assess the potential of SGLT-2 inhibitors as a CVD treatment option.

Main Methods:

  • Review of recent clinical data and studies on SGLT-2 inhibitors.
  • Analysis of cardiovascular outcomes associated with SGLT-2 inhibitor use in T2DM.
  • Examination of data on MACE reduction in relevant patient populations.

Main Results:

  • Antidiabetic medications, particularly SGLT-2 inhibitors, are associated with reduced MACE.
  • SGLT-2 inhibitors demonstrate potential cardiovascular benefits in patients with CVD.
  • Evidence suggests SGLT-2 inhibitors can help prevent CVD in diverse patient groups.

Conclusions:

  • SGLT-2 inhibitors represent a significant advancement in managing cardiovascular risk in T2DM.
  • These agents show potential value in preventing CVD and improving outcomes in patients with T2DM and existing cardiovascular conditions.
  • Further research supports the role of SGLT-2 inhibitors in comprehensive cardiovascular risk management.

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.7K
Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo10:35

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo

Published on: April 6, 2022

3.1K

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
535
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
472
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
510
Secondary Active Transport01:55

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
136.2K
Secondary Active Transport01:32

Secondary Active Transport

One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme "pump" embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
9.1K
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
27.0K